Our multi-disciplinary team includes ear nose and throat (ENT) surgeons, neuroscientists, audiologists, engineers, regulatory experts, clinicians, product designers and many others whose unique skills and capabilities contribute to the Neuromod approach.
We collaborate closely with key opinion leading scientists and clinicians in targeted indication areas to develop and clinically evaluate therapies based on our patented technology.
We work with established international medical device contract manufacturers with capacity to meet the quality demands of state of the art production processes as we commercialise on a global scale.
We have developed and patented a non-invasive bi-modal neuromodulation technology that concurrently stimulates the peripheral auditory and somatosensory systems for the treatment of chronic tinnitus. Tinnitus is a condition that affects 10% of the adult population and is commonly known as 'ringing in the ears'. Tinnitus can significantly impact on quality of life, with documented secondary symptoms including anxiety, sleep loss and depression.
Working with world-leading clinicians and scientists in the tinnitus field, we are conducting large-scale international clinical trials to build the evidence-base to support our unique treatment. To date, more than 500 tinnitus patients have been treated with our patented bi-modal neuromodulation technology.
Our product is approved for sale within the European Union (CE marked) and is protected by a growing portfolio of issued and pending US, European and international patents.